CClinicalTrials.gg
CompletedNCT01622140Updated Jan 28, 2021

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

An observational study in Latent Tuberculosis Infection and Tuberculosis, sponsored by Centers for Disease Control and Prevention. Completed at 10 sites in United States. Per ClinicalTrials.gov, last updated 2021-01-28.

Sponsored by Centers for Disease Control and Prevention · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
21,334
Sex
All
01

Study summary

This is a prospective cohort study of persons tested for latent tuberculosis infection at either high risk for exposure to Mycobacterium tuberculosis or high risk for progression to tuberculosis disease. The study will assess the relative performance and cost of three diagnostic tests for latent tuberculosis infection (tuberculin skin test, QuantiFERON-TB Gold In-Tube, and T-SPOT.TB) and will examine the rates of positive results among the cohort. This study will also determine the risk and rate of progression to active TB disease, overall and by the results of the three tests.

02

Conditions studied

  • Latent Tuberculosis Infection
  • Tuberculosis

Keywords

  • T-SPOT.TB
  • QuantiFERON-TB Gold In-Tube
  • Latent tuberculosis infection
  • Tuberculin skin test
  • Discordance
  • Predictive value
  • Tuberculosis disease development
03

In context

Infections

6,687 studies on the registry are indexed under Infections; 807 are open to participants now.

This study's enrollment of 21,334 is above the median of 240 across 2,136 observational studies indexed under Infections.

Browse Infections studies →

Lead sponsor

Centers for Disease Control and Prevention is the lead sponsor of 273 studies on the registry; 2 are open to participants now.

Of its 11 completed or terminated interventional studies of FDA-regulated products, 8 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Individuals at high risk for latent tuberculosis infection or at high risk for progression to tuberculosis from health clinics, hospitals, or health departments at the 10 Tuberculosis Epidemiologic Studies Consortium sites within the United States: California Department of Public Health, Denver Health and Hospital Authority, Duke University, Emory University, Hawaii Department of Health, Maricopa County Department of Public Health, Maryland Department of Public Health, Public Health Seattle-King County, University of Florida Board of Trustees, and University of North Texas Health Science Center

Eligibility criteria

  1. Study participants must be at high risk for latent tuberculosis infection or at high risk for progression to tuberculosis disease, including being a:

    • Close contact of a person with pulmonary tuberculosis who is part of a current contact investigation and the index/source case meets the following criteria:
    1. Culture-positive, OR
    2. Culture-negative and smear positive and nucleic acid amplification test-positive.

    Participants may be enrolled before the culture results for the index/source case are available. If the criteria described above are not met once results are available, the participant will be terminated from the study and any collected data will be immediately destroyed.

    A close contact is defined as spending 15 or more hours over a week's period in a shared airspace with a person with active pulmonary tuberculosis while that person was presumed to be infectious.

    • Foreign-born person from a high risk country.
    • Foreign-born person from a medium risk country who moved to the United States within the past 5 years.
    • Person who has spent at least 30 days in total in a high risk country within the last 5 years.
    • Person belonging to a population with a prevalence of latent tuberculosis infection ≥ 25% as demonstrated by local surveys. These populations will vary by site; examples include Mexican immigrants in San Diego, California or homeless drug users in Baltimore, Maryland.
    • HIV-positive person.
  2. Study participants (or a parent/guardian, if applicable) must be willing and able to provide informed consent.

4.2 Subject Exclusion Criteria

Subjects meeting any of the exclusion criteria will be excluded from study enrollment.

  1. People with known current active tuberculosis.
  2. People with a previous anaphylactic reaction to tuberculin.
  3. Persons currently being treated for latent tuberculosis infection.
  4. Persons anticipating or scheduled to permanently leave the United States (e.g., tourists, visiting scholars, exchange students) in less than 2 years from the time of proposed study enrollment.
  5. Foster children.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
21,334 participants (actual)
06

What researchers measure

Primary outcomes

  1. Latent tuberculosis infection

    Time frame: 3 days

  2. Tuberculosis disease at 6 months

    Time frame: 6 months

  3. Tuberculosis disease at 12 months

    Time frame: 12 months

  4. Tuberculosis disease at 18 months

    Time frame: 18 months

  5. Tuberculosis disease at 24 months

    Time frame: 24 months

07

Study locations

10 sites
  • Maricopa County Department of Public Health
    Phoenix, Arizona 85006, United States
  • California Department of Public Health
    Richmond, California 94804, United States
  • Denver Health and Hospitals Authority
    Denver, Colorado 80204, United States
  • University of Florida Board of Trustees
    Gainesville, Florida 32611, United States
  • Emory University
    Atlanta, Georgia 30303, United States
  • Hawaii Department of Health
    Honolulu, Hawaii 96817, United States
  • Maryland Department of Public Health
    Baltimore, Maryland 21201, United States
  • Duke University
    Durham, North Carolina 27708, United States
  • University of North Texas Health Science Center
    Fort Worth, Texas 76107, United States
  • Public Health Seattle-King County
    Seattle, Washington 98104, United States
08

References and documents

Publications

  • Ho CS, Feng PI, Narita M, Stout JE, Chen M, Pascopella L, Garfein R, Reves R, Katz DJ; Tuberculosis Epidemiologic Studies Consortium. Comparison of three tests for latent tuberculosis infection in high-risk people in the USA: an observational cohort study. Lancet Infect Dis. 2022 Jan;22(1):85-96. doi: 10.1016/S1473-3099(21)00145-6. Epub 2021 Sep 6. PubMed 34499863 ↗
  • Ahmed A, Feng PI, Gaensbauer JT, Reves RR, Khurana R, Salcedo K, Punnoose R, Katz DJ; TUBERCULOSIS EPIDEMIOLOGIC STUDIES CONSORTIUM. Interferon-gamma Release Assays in Children <15 Years of Age. Pediatrics. 2020 Jan;145(1):e20191930. doi: 10.1542/peds.2019-1930. Erratum In: Pediatrics. 2020 May;145(5):e20200467. doi: 10.1542/peds.2020-0467. PubMed 31892518 ↗
  • Stout JE, Wu Y, Ho CS, Pettit AC, Feng PJ, Katz DJ, Ghosh S, Venkatappa T, Luo R; Tuberculosis Epidemiologic Studies Consortium. Evaluating latent tuberculosis infection diagnostics using latent class analysis. Thorax. 2018 Nov;73(11):1062-1070. doi: 10.1136/thoraxjnl-2018-211715. Epub 2018 Jul 7. PubMed 29982223 ↗
09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 28, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01622140
Lead sponsor
Centers for Disease Control and Prevention
Responsible party
Sponsor
First posted
Jun 18, 2012
Start date
Oct 2012
Primary completion
Dec 31, 2020
Completion
Dec 31, 2020
Last update
Jan 28, 2021

Study contacts

Christine Ho, MD
principal investigator · Centers for Disease Control and Prevention
Dolly Katz, PhD
principal investigator · Centers for Disease Control and Prevention
Thara Venkatappa, PhD
principal investigator · Centers for Disease Control and Prevention

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion